Recent Company News

• 04:05 AM ET Apr 16, 2026
  

  Shanghai Yuyuan Tourist Mart reports Q1 net income attributable CNY157.0M, +202.9% y/y (CNY 5.00, 0.00)

• 04:59 AM ET Apr 14, 2026
  

  Shanghai Fosun Pharmaceutical (Group) Co. receives clinical trial approval for FKC289 injection (HK$19.74, 0.00)

• 03:03 AM ET Apr 10, 2026
  

  Fosun seeking best way to divest its 20.45% stake in BCP -- Expresso (€0.91, 0.00)

• 09:35 PM ET Apr 07, 2026
  

  StreetAccount Sector Summary - China Healthcare March Recap

• 09:03 PM ET Apr 06, 2026
  

  Fosun International upgraded to buy at Industrial Securities (HK$4.29, 0.00)

• 04:57 AM ET Apr 02, 2026
  

  Shanghai Fosun Pharma CFO Chen Zhanyu steps down due to work arrangements, effective immediately (HK$20.80, 0.00)

• 07:08 AM ET Apr 01, 2026
  

  Fosun International Holds 2025 Annual Results Presentation: Fosun has the Ability to Navigate Through Cycles

• 05:36 AM ET Mar 31, 2026
  

  Guo Guangchang: Fosun International's NAV reaches HKD18.1 Per Share, Focusing Resources on Core, High--Growth Areas